IGF-1 LR3 vs Tesamorelin: What the Research Shows
IGF-1 LR3 and Tesamorelin side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider IGF-1 LR3 if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
Consider Tesamorelin if…
- you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[10]
- you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[16]
What they have in common
- Only animal or lab studies of IGF-1 LR3 were found (e.g. rat): The IGF-I variants were 2.5-3 times more potent than IGF-I at restoring growth in diabetic rats.[15]
Spec comparison
Showing 11 of 13 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.
| Field | IGF-1 LR3 | Tesamorelin |
|---|---|---|
| Class | IGF-1 analog | GHRH analog |
| Also called | LR3 | tesa, Egrifta |
| Category | Growth hormone | Growth hormone |
| FDA status | Not FDA approved · research chemical | FDA approved (Egrifta) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.3)IGF-1 and its analogues (LR3 is an IGF-1 analogue) are prohibited in S2.3, at all times. | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | 563 min half-life in wound fluid (versus 872 min for IGF-I)wound chamber (rat) (rat) · The American journal of physiology 1999, PMID 10198302 | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) |
| Evidence strength | Human observational evidence, 3 of 4Strongest: Growth hormone & IGF research 2010, PMID 20675162 | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 |
| Human studies we summarised | 1 human (0 randomized or controlled) of 12 summarised | 12 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 0.1 mg, 1 mg | 2 mg, 5 mg, 10 mg, 20 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
IGF-1 LR3 and Tesamorelin together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
A peptide with a labelled product versus one with no human trial
In tesamorelin's phase 3 HIV trial, IGF-I rose 81.0% on tesamorelin and fell 5.0% on placebo.[16]
In pigs, LR3IGF-I infusion lowered mean plasma GH by 23% and the area under the GH peaks by 60%.[17]
In adults with mild cognitive impairment and healthy older adults, GHRH treatment showed a positive effect on executive function (P=.005).[18]
Label limits for tesamorelin and unknowns for IGF-1 LR3
Egrifta's label restricts its use to excess abdominal fat in HIV-infected adults with lipodystrophy and says it is not for weight loss management.[10]
The Egrifta WR label gives a mean elimination half-life of 11 minutes for tesamorelin in healthy subjects after a single subcutaneous 1.28 mg dose.[10]
A product analysis states that the effects of His-tagged Long-R3-IGF-I in humans have not been elucidated or described.[4]
Common questions
IGF-1 LR3 vs tesamorelin: which is better for fat loss?
No human fat-loss study of IGF-1 LR3 is cited here. The Egrifta WR label says tesamorelin is not indicated for weight loss management.[10]
Does tesamorelin act like IGF-1?
Tesamorelin raised IGF-I in its phase 3 trial (81.0% against a 5.0% fall on placebo). IGF-1 LR3 is covered above as an IGF-1 analogue studied in animals.[16]
Is IGF-1 LR3 approved like tesamorelin?
No. Tesamorelin is sold as Egrifta for a defined indication, while IGF-1 LR3 has no label or human trial in our evidence.[10]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
- 4Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
- 5IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
- 6Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
- 7Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
- 8An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 9Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 10EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 12Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 13The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 14PubMed search: ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
- 16Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 17Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.The Journal of endocrinology · 1997PMID 9488001Accessed 2 Oct 2026
- 18Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.Archives of neurology · 2012PMID 22869065Accessed 2 Oct 2026
Found an error? Report a correction.